Hostname: page-component-848d4c4894-x5gtn Total loading time: 0 Render date: 2024-06-09T13:09:20.038Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of the immunogenicity, efficacy and safety of 10 μg and 20 μg of a hepatitis B vaccine: a prospective randomized trial

Published online by Cambridge University Press:  19 October 2009

E. K. Yeoh ,
C. L. Lai ,
W. K. Chang  and
H. Y. Lo
E. K. Yeoh
Affiliation:
Queen Elizabeth Hospital, Hong Kong
C. L. Lai
Affiliation:
University Department of Medicine, Queen Mary Hospital, Hong Kong
W. K. Chang
Affiliation:
Virus Unit, Medical and Health Department, Hong Kong
H. Y. Lo
Affiliation:
Queen Elizabeth Hospital, Hong Kong
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Four thousand and one hospital staff were screened for hepatitis B virus (HBV) markers in a vaccination programme in Hong Kong. The seropositivity rate for HBsAg, anti-HBs and anti-HBc were significantly higher in the 3160 existing hospital staff than in 841 new recruits. Of the subjects negative for HBV markers, 605 were randomized to receive three doses of either 10 or 20 μg of the Merck Institute vaccine (HB-VAX). Compared with the 20 μg dose, vaccination with the 10 μg dose results in equal immunogenicity and efficacy at the completion of the three injections but induced a slower response rate and lower anti-HBs titres with the first two doses. The commonest side-effect of local soreness was less with the 10 μg dose. We conclude that (1) hospital staff working in high endemic areas should be vaccinated on recruitment and (2) the 10 μg dose of HB-VAX can replace the recommended 20 μg dose for adults, being cheaper and as efficacious.

Type
Research Article
Information
Journal of Hygiene , Volume 96 , Issue 3 , June 1986 , pp. 491 - 499
Copyright
Copyright © Cambridge University Press 1986

References

REFERENCES

Ayoola, E. A. (1984). The immune response of healthy Nigerian adults to small doses of hepatitis B vaccine: comparison of 10 and 20 μg doses. Journal of Medical Virology 13, 223–225.CrossRefGoogle Scholar
Beasley, R. P. (1982). Hepatitis B virus as the etiologic agent in hepatocellular carcinoma – epidemiologic considerations. Hepatology 2, 21–26S.Google Scholar
Deinhardt, F., Zachoval, R., Jilg, W., Lourbeer, B. & Rogoendorf, M. (1983). Immune responses to active and passive-active vaccination against hepatitis. Journal of Injection 7 (I), 21–25.Google ScholarPubMed
Fleiss, J. L. (1973). In Statistical Methods for Rates and Proportions. New York: John Wiley.Google Scholar
Hilleman, M., Buynak, E., Roehm, R., Tytell, A., Berthland, A. & Lampson, S. (1975). Purified and inactivated human hepatitis B vaccine: progress report. American Journal of Medical Science 270, 401–404.CrossRefGoogle ScholarPubMed
Hollinger, F. B., Adam, E., Heiberg, D. & Melnick, J. L. (1982). Response to hepatitis B vaccine in a young adult population. In Viral Hepatitis (eds. Szmuness, W., Alter, H. J. & Maynard, J. E.), pp. 451–456. New York: Franklin Institute Press.Google Scholar
Koff, R. S. (1978). Specific epidemiologic problems. In Viral Hepatitis (ed. Koff, R. S.), Clinical Gastroenlerology Monograph Series, pp. 115–119. New York: John Wiley.Google Scholar
Krugman, S., Holley, H. P., Davidson, M., Sunberkoff, M. S. & Matsariotis, N. (1981). Immunogenic effect of inactivated hepatitis B vaccine: comparison of 20 and 40 μg doses. Journal of Medical Virology 8, 119–121.CrossRefGoogle Scholar
Lai, C. L., Wu, P. C., Yeoh, E. K., Lok, A. S. F., Lin, H. J., Lam, S. K. & Todd, D. (1984). Hepatocellular carcinoma and the hepatitis B virus. In Viral Hepatitis B Infection in the Western Pacific Region: Vaccine and Control (ed. Lam, S. K., Lai, C. L. & Yeoh, E. K.), pp. 3–16. Singapore: World Scientific.Google Scholar
McAlur, W. J., Buynak, E. B., Maigetter, R. Z., Wampler, D. E., Miller, W. J. & Hilleman, M. R. (1984). Human hepatitis B vaccine from recombinant yeast. Nature 12, 178–179.CrossRefGoogle Scholar
Mosley, J. M., Edwards, V. M., Casey, C., Redeker, A. G. & White, E. (1975). Hepatitis B virus infection in dentists. New England Journal of Medicine 293, 729–734.CrossRefGoogle ScholarPubMed
Papaevangelou, G., Vissoulis, C., Roumeliotou-Karayannis, A., Kolaitis, N. & Kruoman, S. (1982). Comparison of safety and immunogenicity of adw and ayw hepatitis B vaccines. Journal of Medical Virology 9, 231–236.Google Scholar
Papaevanoelou, G., Roumeliotou-Karayannis, A., Vissoulis, C., Stathopoulou, P., Kolaitis, N. & Krugman, S. (1983). Reduction of the dose of hepatitis B vaccine. Journal of Infection 7 (I), 69–70.CrossRefGoogle Scholar
Scolnick, E. M., McLean, A. A., West, D. J., McAlur, W. J., Miller, W. J. & Buynak, E. B. (1984). Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. Journal of the American Medical Association 251, 2812–2815.Google Scholar
Szmuness, W., Stevens, C. E.Harley, E. J., Zang, E. A., Oleszko, W. R., William, D. C., Sadovsky, R., Morrion, J. M. & Kellner, A. (1980). Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. New England Journal of Medicine 303, 833–841.CrossRefGoogle Scholar
Szmuness, W., Stevens, C. E., Zang, E. A., Harley, E. J. & Kellner, A. (1981). A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepalology 1, 377–385.CrossRefGoogle ScholarPubMed
Yeoh, E. K., Chang, W. K. & Kwan, J. P. W. (1984). Epidemiology of viral hepatitis B infection in Hong Kong. In Viral Hepatitis B Infection in the Western Pacific Region: Vaccine and Control (ed. Lam, S. K., Lai, C. L. & Yeoh, E. K.), pp. 34–42. Singapore: World Scientific.Google Scholar